Proving the Business Case for the Internet of Things

CeQur takes control of Calibra insulin-delivery wearable

Steve Rogerson
July 25, 2018

Swiss firm CeQur has acquired selected assets of Calibra Medical, one of the Johnson & Johnson diabetes care companies. The transaction includes an exclusive worldwide licence for the OneTouch Via wearable, on-demand insulin-delivery system.
The Calibra system lets people with diabetes discreetly and conveniently deliver rapid-acting insulin at mealtimes. Financial terms of the acquisition were not disclosed.
"CeQur is dedicated to simplifying insulin dosing for people with diabetes, so that they can live healthier, more satisfying lives," said Robert Farra, chief executive officer of CeQur. "Clinical studies and real-world experience have shown that wearable, on-demand insulin delivery provides an ideal solution to the pervasive challenge of mealtime insulin delivery. The Calibra device is a perfect complement to PAQ, our basal and bolus insulin-infusion device. Both wearable devices provide simple, discreet, three-day insulin delivery without the barriers and discomfort created by injections."
CeQur plans to launch OneTouch Via under a new name in mid-2019, following transfer of manufacturing equipment.
"This device will enable us to begin reaching the diabetes community with simple, discreet, three-day insulin delivery that will free people from having to inject multiple times per day," said Farra.
Two million people with type-two diabetes in the USA take multiple daily insulin injections to control their blood glucose levels (HbA1c). Clinical practice guidelines published by the American Diabetes Association generally point to HbA1c levels below seven per cent as reasonable targets to help prevent diabetes complications. An estimated 70 per cent of insulin users in the USA do not achieve this goal, primarily due to missed insulin injections. Lifestyle restrictions, injection problems and social stigma are all barriers to consistent and appropriate insulin therapy.
Results of a global 62-site clinical study presented at the American Diabetes Association 2018 Scientific Sessions comparing OneTouch Via to insulin pens to initiate and maintain bolus insulin dosing among 278 people with type-two diabetes showed that this device provided positive clinical benefits with less glycaemic variability than pens, significantly higher ease of use and patient satisfaction scores, and similar safety.
"Basal and bolus insulin therapy works when we have the tools to determine the appropriate insulin doses and deliver them in a convenient way," said Richard Bergenstal, endocrinologist and executive director of the International Diabetes Center in Minneapolis. "Results from the Calibra clinical study were quite impressive, showing that the device provides an easy way for patients to deliver bolus insulin at mealtimes on top of an individualised basal insulin injection. Having options available for patients that makes insulin delivery easier, more discreet and convenient is one way to help improve diabetes management."
Eric Milledge, executive chairman of CeQur, added: "The Calibra device is well designed with impressive clinical results. The number of people with diabetes who require insulin will continue to grow. Given the proven benefits of this device, as well as the range of patients it can support, CeQur will improve the health and simplify the lives of these individuals."